Cronos Group Inc.
NASDAQ:CRONDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $1.16B
- Beta
- 1.25
- P/E (TTM)
- -488.3
- EPS (TTM)
- -$0.01
Volume 1.13M
Average 1.51M
CRON Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cronos Group Inc.NASDAQ: CRON
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $1.39M rose 75.7% year over year, ahead of the +25.5% change in trailing-twelve-month research & development. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at -30.3% a year.
Context
- Research & development amounted to 3.0% of revenue in FY2025, down 0.6 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +75.7% holds above the trailing-twelve-month pace of +25.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 4.45M USD
- Year-over-year change
- +5.2%
- 4-year CAGR
- -32.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.45M | +5.2% |
| FY2024 | 2024-12-31 | 4.23M | -27.6% |
| FY2023 | 2023-12-31 | 5.84M | -55.5% |
| FY2022 | 2022-12-31 | 13.13M | -39.9% |
| FY2021 | 2021-12-31 | 21.84M | — |
Research & Development vs competitors
How CRON compares with its peers on the latest reported figures
- CRON's LTM Mar 2026 research & development of $5.05M is the 9th highest of the 11 companies compared; the peer median is $100.21M.
- Its year-over-year change of +25.5% is the 5th highest of 10, against a peer median of +20.2%.
- Research & development amounts to 2.5% of revenue for CRON, versus a peer median of 15.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Jun 2026 | $255.77M | +11.4% | +6.3% | 243.6% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $140.37M | +74.2% | — | — |
| LTM Mar 2026 | $119.69M | +35.0% | +11.4% | 16.3% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $92.49M | +20.2% | +4.7% | 12.8% | |
| LTM Mar 2026 | $31.37M | -7.3% | -22.9% | 15.3% | |
| LTM Mar 2026 | $18.4M | -65.5% | -30.8% | 1.8% | |
| LTM Mar 2026 | $5.05M | +25.5% | -30.3% | 2.5% | |
| LTM Mar 2026 | $3.31M | +25.5% | +9.3% | 3.8% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CRON) | $100.21M | +20.2% | +7.8% | 15.3% | |
Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 64.56M | 86.75M | 87.24M | 117.62M | 149.15M |
| Cost of Revenue | 82.15M | 71.31M | 75.33M | 92.42M | 87.45M |
| Gross Profit | (17.59M) | 15.44M | 11.91M | 25.2M | 61.7M |
| Gross Margin | -27.3% | 17.8% | 13.7% | 21.4% | 41.4% |
| Research & Development | 21.84M | 13.13M | 5.84M | 4.23M | 4.45M |
| Selling, General & Admin | 121.68M | 100.73M | 80.93M | 76.82M | 63.76M |
| Operating Expenses | 274.38M | 126.86M | 96.71M | 101.73M | 79.54M |
| Depreciation & Amortization | 15.4M | 13.12M | 8.11M | 9.34M | 14.48M |
| EBITDA | (150.13M) | (91.27M) | (71.8M) | (50.21M) | (3.36M) |
| EBITDA Margin | -232.5% | -105.2% | -82.3% | -42.7% | -2.3% |
| Operating Income | (291.97M) | (111.43M) | (84.8M) | (76.53M) | (17.84M) |
| Operating Margin | -452.2% | -128.4% | -97.2% | -65.1% | -12.0% |
| Interest Income | 9.07M | 22.51M | 51.24M | 52.02M | 40.66M |
| Interest Expense | 27K | 13K | 0 | 0 | 0 |
| Other Income / Expenses | 163.46M | (9.58M) | 11.13M | 113.12M | 419.21K |
| Income Before Tax | (128.51M) | (121M) | (73.67M) | 36.59M | (17.42M) |
| Pre-Tax Margin | -199.1% | -139.5% | -84.4% | 31.1% | -11.7% |
| Income Tax Expense | (431K) | 34.18M | (3.23M) | (3.44M) | (14.44M) |
| Net Income | (396.11M) | (168.73M) | (73.96M) | 41.08M | (9.61M) |
| Net Margin | -613.5% | -194.5% | -84.8% | 34.9% | -6.4% |
| EPS (Basic) | (1.07) | (0.45) | (0.19) | 0.11 | (0.03) |
| EPS (Diluted) | (1.07) | (0.45) | (0.19) | 0.11 | (0.03) |
| Weighted Avg Shares | 370.39M | 376.96M | 403.4M | 382.06M | 385.31M |
| Weighted Avg Shares (Diluted) | 370.39M | 376.96M | 380.97M | 385.56M | 385.31M |
Cronos Group Inc.
NASDAQ:CRON
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.